<HashMap><database>MetabolomicsWorkbench</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>http://www.metabolomicsworkbench.org/rest/study/study_id/ST001466/mwtab</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><technology_type>NMR</technology_type><disease>Graft Versus Host Disease</disease><full_dataset_link>http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&amp;StudyID=ST001466</full_dataset_link><study_factor>Treatment Protocol:allogenic</study_factor><study_factor>Treatment Protocol:naive</study_factor><study_factor>Treatment Protocol:syngenic</study_factor><tissue>Spleen</tissue><sample_protocol>NMR data.</sample_protocol><repository>MetabolomicsWorkbench</repository><data_protocol></data_protocol><omics_type>Metabolomics</omics_type><species>Mus Musculus</species><submitter_affiliation>University of Kentucky</submitter_affiliation><metabolite_name>Glu-4_1</metabolite_name><metabolite_name>Asp-3a_1</metabolite_name><metabolite_name>AXP-8_1</metabolite_name><metabolite_name>NAD+-N1'_1</metabolite_name><metabolite_name>AXP-2_1</metabolite_name><metabolite_name>aGlc_1</metabolite_name><metabolite_name>aGlc_2</metabolite_name><metabolite_name>bGlc_1</metabolite_name><metabolite_name>Asp-3a_4</metabolite_name><metabolite_name>bGlc_2</metabolite_name><metabolite_name>Asp-3b_1</metabolite_name><metabolite_name>GSSG-12_1</metabolite_name><metabolite_name>Asp-3a_2</metabolite_name><metabolite_name>Asp-3b_2</metabolite_name><metabolite_name>Asp-3a_3</metabolite_name><metabolite_name>Glu-3-a_2</metabolite_name><metabolite_name>Glu-3-b_1</metabolite_name><metabolite_name>Glu-3-a_1</metabolite_name><metabolite_name>Gly_1</metabolite_name><metabolite_name>Glu-3-a_4</metabolite_name><metabolite_name>Glu-3-a_3</metabolite_name><metabolite_name>Glu-3-b_2</metabolite_name><metabolite_name>GSH+GSSG-4_2</metabolite_name><metabolite_name>Glu-3-a_5</metabolite_name><metabolite_name>GSH+GSSG-3_2</metabolite_name><metabolite_name>GSH+GSSG-4_1</metabolite_name><metabolite_name>Lac-2_2</metabolite_name><metabolite_name>Ala-3_1</metabolite_name><metabolite_name>Lac-2_1</metabolite_name><metabolite_name>Ala-3_2</metabolite_name><metabolite_name>NAD+-A1'_1</metabolite_name><metabolite_name>Gln+Glu-2_4</metabolite_name><metabolite_name>Gln+Glu-2_3</metabolite_name><metabolite_name>Gln+Glu-2_2</metabolite_name><metabolite_name>Gln-4_2</metabolite_name><metabolite_name>Gln+Glu-2_1</metabolite_name><metabolite_name>Gln-4_1</metabolite_name><metabolite_name>GSH+GSSG-3_1</metabolite_name><metabolite_name>Lac-3_1</metabolite_name><metabolite_name>Succinate-2,3_1</metabolite_name><metabolite_name>Lac-3_2</metabolite_name><metabolite_name>GSH-8_1</metabolite_name><metabolite_name>DSS_1</metabolite_name><metabolite_name>Ace-2_1</metabolite_name><metabolite_name>UXP-1'_1</metabolite_name><metabolite_name>AXP-1'_1</metabolite_name><metabolite_name>Glycogen_1</metabolite_name><name_synonyms>Pulmonary Injury, E-Cigarette or Vaping Product Use-Associated Lung Injury, Injury, Lung, Transplantation, Pulmonary Injuries, Metabonomic, Lung Injuries, Chronic Lung Injury, Metabonomics, EVALI, Lung Injury, Cell, Injuries, E Cigarette Use Associated Lung Injury, Vaping Product Use Associated Lung Injury, lien., Vaping Product Use-Associated Lung Injury, Chronic, E-Cigarette Use-Associated Lung Injury, Chronic Lung Injuries, E Cigarette or Vaping Product Use Associated Lung Injury, Metabolomic, Pulmonary, EVALIs</name_synonyms></additional><is_claimable>false</is_claimable><name>Metabolomics of lung injury after allogeneic hematopoietic cell transplantation Spleen - NMR HSQC</name><description/><dates><publication></publication></dates><accession>ST001466</accession><cross_references><TAXONOMY>10090</TAXONOMY></cross_references></HashMap>